Shearman & Sterling represented Barclays Capital Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC, as representatives of the several underwriters in connection with Thermo Fisher Scientific Inc.’s public offering of $1 billion aggregate principal amount of 2.250% Senior Notes due 2016 and $1.1 billion aggregate principal amount of 3.600% Senior Notes due 2021. Thermo Fisher is a leader in medical equipment and diagnostics, providing analytical instruments, laboratory equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The proceeds of the offering were used to finance its acquisition of Phadia, a global leader in allergy and autoimmunity diagnostics.